Development of a modified ABC method among Helicobacter pylori infected but serum pepsinogen test‐negative individuals

Although the ABC method for gastric cancer (GC) screening has been widely adopted in Japan, it may not be suitable for other countries due to population heterogeneity and different tumor histology. We aim to develop a modified ABC method to improve GC screening performance, especially among Helicobacter pylori (Hp) infected but serum pepsinogen (sPG) test‐negative individuals.

[1]  Wenqiang Wei,et al.  Prediction models for gastric cancer risk in the general population: a systematic review. , 2022, Cancer prevention research.

[2]  M. Rugge,et al.  Pepsinogen II in gastritis and Helicobacter pylori infection , 2022, Helicobacter.

[3]  M. Plummer,et al.  The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study , 2021, The Lancet. Public health.

[4]  N. Nishimura,et al.  Feasibility of endoscopic evaluation of Helicobacter pylori infection status by using the Kyoto classification of gastritis in the population‐based gastric cancer screening program: A prospective cohort study , 2021, Health science reports.

[5]  Xuan Huang,et al.  Performance evaluation of four prediction models for risk stratification in gastric cancer screening among a high-risk population in China , 2021, Gastric Cancer.

[6]  K. Pan,et al.  Screening for gastric cancer in China: Advances, challenges and visions , 2021, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[7]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[8]  C. de Martel,et al.  Time trends and other sources of variation in Helicobacter pylori infection in mainland China: A systematic review and meta‐analysis , 2020, Helicobacter.

[9]  T. Oyama,et al.  Usefulness and Limitations of a Serum Screening System to Predict the Risk of Gastric Cancer , 2020, Internal medicine.

[10]  Gerrit Hirschfeld,et al.  cutpointr: Improved Estimation and Validation of Optimal Cutpoints in R , 2020, J. Stat. Softw..

[11]  Seonwoo Kim,et al.  Determination of cutoff values for biomarkers in clinical studies , 2020 .

[12]  Shu-dong Yang,et al.  Community-Based Pilot Study of a Screening Program for Gastric Cancer in a Chinese Population , 2019, Cancer Prevention Research.

[13]  Y. J. Kwon,et al.  Role of Serum Pepsinogen II and Helicobacter pylori Status in the Detection of Diffuse-Type Early Gastric Cancer in Young Individuals in South Korea , 2019, Gut and liver.

[14]  G. Meng,et al.  The relationship between Helicobacter pylori infection and depressive symptoms in the general population in China: The TCLSIH cohort study , 2019, Helicobacter.

[15]  C. S. Bang,et al.  Prediction of Chronic Atrophic Gastritis and Gastric Neoplasms by Serum Pepsinogen Assay: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy , 2019, Journal of clinical medicine.

[16]  Yuan Yuan,et al.  Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study , 2019, Gut.

[17]  A. Jemal,et al.  Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. , 2019, The Lancet. Global health.

[18]  C. Hamashima.  Update version of the Japanese Guidelines for Gastric Cancer Screening. , 2018, Japanese journal of clinical oncology.

[19]  D. Vrbanec,et al.  Gastric cancer detection using the serum pepsinogen test method , 2018, Tumori.

[20]  Y. Liu,et al.  Gastric Cancer Screening by Combined Determination of Serum Helicobacter pylori Antibody and Pepsinogen Concentrations: ABC Method for Gastric Cancer Screening , 2018, Chinese medical journal.

[21]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[22]  Yoshiharu Saito,et al.  Serum pepsinogen levels indicate the requirement of upper gastrointestinal endoscopy among Group A subjects of ABC classification: a multicenter study , 2018, Journal of Gastroenterology.

[23]  M. Inoue,et al.  Changing trends in the prevalence of H. pylori infection in Japan (1908–2003): a systematic review and meta-regression analysis of 170,752 individuals , 2017, Scientific Reports.

[24]  M. Inoue,et al.  Changing trends in the prevalence of H. pylori infection in Japan (1908–2003): a systematic review and meta-regression analysis of 170,752 individuals , 2017, Scientific Reports.

[25]  S. Ng,et al.  Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. , 2017, Gastroenterology.

[26]  Yulian Wu,et al.  The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China: a diagnostic clinical research , 2017, BMC Gastroenterology.

[27]  R. Bostick,et al.  A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study , 2017, American Journal of Gastroenterology.

[28]  Fumie 文恵 Ikeda 池田,et al.  Combination of Helicobacter pylori Antibody and Serum Pepsinogen as a Good Predictive Tool of Gastric Cancer Incidence: 20-Year Prospective Data From the Hisayama Study , 2016, Journal of epidemiology.

[29]  Y. Takwoingi,et al.  Non-invasive diagnostic tests for Helicobacter pylori infection. , 2016, The Cochrane database of systematic reviews.

[30]  M. Inoue,et al.  Prediction of the 10‐year probability of gastric cancer occurrence in the Japanese population: the JPHC study cohort II , 2016, International journal of cancer.

[31]  Shinya Sakagami,et al.  Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels - The ABC Method , 2016, Digestion.

[32]  Jaw-Town Lin,et al.  A tool to predict risk for gastric cancer in patients with peptic ulcer disease on the basis of a nationwide cohort. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[33]  S. Kodashima,et al.  The Efficacy of Gastric Cancer Risk A, B, C, D Gastritis Screening (ABC Screening) for the Detection of the PG-Negative Gastric Cancer: 154 , 2014 .

[34]  N. Yamamichi,et al.  Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer , 2014, International journal of cancer.

[35]  Fei Kong,et al.  Serum pepsinogen II is a better diagnostic marker in gastric cancer. , 2012, World journal of gastroenterology.

[36]  N. Yamamichi,et al.  Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis , 2012, International journal of cancer.

[37]  Xianghong Zhang,et al.  Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14‐year follow up result in a rural Chinese community , 2012, International journal of cancer.

[38]  K. Chayama,et al.  Serum screening for detection of high‐risk group for early‐stage diffuse type gastric cancer in Japanese , 2012, Journal of gastroenterology and hepatology.

[39]  K. Miki.  Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels — “ABC method” , 2011, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[40]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[41]  Yu-Min Lin,et al.  McNemar Test Is Preferred for Comparison of Diagnostic Techniques , 2008 .

[42]  N. Yamamichi,et al.  Risk of gastric cancer in asymptomatic, middle‐aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels , 2008, International journal of cancer.

[43]  Khean Lee Goh,et al.  Screening for gastric cancer in Asia: current evidence and practice. , 2008, The Lancet. Oncology.

[44]  N. Lunet,et al.  Smoking and gastric cancer: systematic review and meta-analysis of cohort studies , 2008, Cancer Causes & Control.

[45]  A. Axon,et al.  Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients , 2006, Gut.

[46]  A. Kaneda,et al.  High Levels of Aberrant DNA Methylation in Helicobacter pylori–Infected Gastric Mucosae and its Possible Association with Gastric Cancer Risk , 2006, Clinical Cancer Research.

[47]  Y. Yamaji,et al.  Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study , 2005, Gut.

[48]  F. T. ten Kate,et al.  Geographic Pathology of Helicobacter pylori Gastritis , 2005, Helicobacter.

[49]  N. Yoshimura,et al.  Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer , 2004, International journal of cancer.

[50]  Hwoong-Yong Jung,et al.  Profile of Aberrant CpG Island Methylation Along the Multistep Pathway of Gastric Carcinogenesis , 2003, Laboratory Investigation.

[51]  A. Rashid,et al.  Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer , 2003, Gut.

[52]  L. Hansson,et al.  Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. , 2001, Gastroenterology.

[53]  M. Blaser,et al.  Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. , 2000, Journal of the National Cancer Institute.

[54]  M. Blaser,et al.  Helicobacter pylori antibodies in relation to precancerous gastric lesions in a high-risk Chinese population. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[55]  S. Kikuchi,et al.  The association of smoking and drinking habits with serum pepsinogens. , 1995, International journal of epidemiology.

[56]  W. Blot,et al.  Precancerous gastric lesions in a population at high risk of stomach cancer. , 1993, Cancer research.

[57]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[58]  J. Rotter,et al.  Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. , 1982, Gastroenterology.

[59]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[60]  Jiang Yehu.  Epidemiological investigation on Helicobacter pylori infection and serum pepsinogen in population undergoing health check-up , 2015 .

[61]  E. Bedel.  Relationship between , 2009 .

[62]  R. P. Blankfield,et al.  Helicobacter pylori infection and the development of gastric cancer. , 2001, The New England journal of medicine.